Home › Research › Clinical trials
Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1
Sophie Dardenne, Julien Delrieu, Sandrine Sourdet, Christelle Cantet, Sandrine Andrieu, Hélène Mathiex-Fortunet, Bertrand Fougère, Bruno Vellas. Journal of Alzheimer's disease : JAD, 2017
Topic: Brain imaging, connectivity and assessment
1,307 patients with SCD and with CDR = 0 at baseline were included. During the 5 years of follow-up, 519 patients showed cognitive decline. Incidence of aggravation score of CDR was 13.40% person years (95% CI [12.24-14.56]). Results showed a significant relationship between the McNair and Kahn Scale score and decline in cognitive performance (HR 1.012; 95% CI [1.002-1.021]; p = 0.0156). Among the 20 items, 5 were statistically significant to predict cognitive decline after adjustment. SCD is a promising indicator of memory impairment. Our study found that using the McNair and Kahn scale can predict cognitive decline. A 5-item version of this scale could be used to screen patients in clinical practice and in clinical research.
Key findings
- 1,307 patients with SCD and with CDR = 0 at baseline were included.
- During the 5 years of follow-up, 519 patients showed cognitive decline.
- Incidence of aggravation score of CDR was 13.40% person years (95% CI [12.24-14.56]).
- Results showed a significant relationship between the McNair and Kahn Scale score and decline in cognitive performance (HR 1.012; 95% CI [1.002-1.021]; p = 0.0156).
- Among the 20 items, 5 were statistically significant to predict cognitive decline after adjustment.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Participants1,307
- Effect size13.40%; HR 1.012
- Evidence strengthHigh
How this study scored 83/100
Published in a peer-reviewed journal, and it is a large phase 3 trial. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and free to read, so those were left out: it earned 49 of the 59 points we could judge it on, which is 83 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A large phase 3 trial (from PubMed type “Clinical Trial, Phase III”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,307 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28984580) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 49 / 59 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 49 of the 59 points we could judge it on is 83 out of 100. |
| Total | 83 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Dardenne, S., Delrieu, J., Sourdet, S., Cantet, C., Andrieu, S., Mathiex-Fortunet, H., et al. (2017). Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-170229
Vancouver
Dardenne S, Delrieu J, Sourdet S, Cantet C, Andrieu S, Mathiex-Fortunet H, et al. Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. Journal of Alzheimer's disease : JAD. 2017. doi:10.3233/jad-170229. PMID: 28984580.
BibTeX
@article{dardenne2017-28984580,
author = {Dardenne, Sophie and Delrieu, Julien and Sourdet, Sandrine and Cantet, Christelle and Andrieu, Sandrine and Mathiex-Fortunet, Hélène and Fougère, Bertrand and Vellas, Bruno},
title = {{Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1}},
journal = {Journal of Alzheimer's disease : JAD},
year = {2017},
doi = {10.3233/jad-170229},
pmid = {28984580},
url = {https://doi.org/10.3233/jad-170229}
}
Related studies in Clinical trials
Also in Clinical trials
10 studies in the library are filed under Clinical trials with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Clinical trials hub.